Net Loss Per Share (Tables)

9 Months Ended

Apr. 30, 2026

Schedule of Net Loss Per Share, Basic and Diluted

The computation of basic and diluted net loss per share consisted of the following:


	Three Months Ended April 30,				Nine Months Ended April 30,
	2026		2025		2026		2025

	(in thousands, except per share data)
Net loss	$	(13,883)	$	(4,125)	$	(59,810)	$	(23,900)
Weighted-average shares used in computing net loss per share, basic and diluted	160,741		154,909		159,662		153,699
Net loss per share, basic and diluted	$	(0.09)	$	(0.03)	$	(0.37)	$	(0.16)

Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share

The following table summarizes the outstanding potentially dilutive securities that were excluded from the computation of diluted net loss per share as their effect would be antidilutive:


	April 30,
	2026	2025

	(in thousands)
Unvested RSUs and shares of common stock	9,089	9,498
Unvested PSAs (1)	1,002	1,072
Share purchase rights under the ESPP	717	926
Stock options	150	171
2028 Notes (2)	3,925	—
2025 Notes (2)	—	7,626
Total	14,883	19,293

(1) The number of unvested PSAs is estimated at 100% of the target number of shares granted and excludes unvested PSAs for which performance conditions have not been established as of April 30, 2026 and 2025, as they are not considered outstanding for accounting purposes. For further information refer to Note 13, Stock-Based Compensation.

(2) Based on the initial conversion price, the entire outstanding principal amount of the 2028 Notes as of April 30, 2026 and the 2025 Notes as of April 30, 2025 would have been convertible into approximately 3.9 million shares and 7.6 million shares of our common stock, respectively